CTOs on the Move

Akorn

www.akorn.com

 
At Akorn, we develop, manufacture and market specialty pharmaceuticals, including prescription, consumer health and animal health products. As an industry leader in branded and generic products in alternate dosage forms such as ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays, we focus each day on our mission to improve lives, through the quality, availability and affordability of our products. Akorn has Research and Development facilities in Vernon Hills, IL and Cranbury, NJ that provide a robust and continuous pipeline of new products. Akorn`s manufacturing facilities are located in Decatur, IL; Somerset, NJ; Amityville, NY and Hettlingen, Switzerland. In ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.akorn.com
  • 1925 West Field Court Suite 300
    Lake Forest, IL USA 60045
  • Phone: 800.932.5676

Executives

Name Title Contact Details
Bill Ostrowski
 Chief Information Officer and SVP Profile

Similar Companies

OMEGA ALPHA PHARMACEUTICALS

OMEGA ALPHA PHARMACEUTICALS INC. is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

US Eye

Be a part of something bigger. Enhance your eye care practice’s capabilities by partnering with a team that understands your business. Contact us today.

Hi-School Pharmacy

Hi-School Pharmacy is a Vancouver, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Diapharma Group Inc.

Diapharma Group Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.